Analysis of follow-up data demonstrated that patients with ABC-DLBCL negative for CCND2 expression had significantly superior progression-free survival than those positive for CCND2 mRNA (χ2 = 8.005, P = 0.005; Figure 2). The gene discussed is CCND2; the disease is diffuse large B-cell lymphoma.